ATE323510T1 - Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen - Google Patents

Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen

Info

Publication number
ATE323510T1
ATE323510T1 AT98950742T AT98950742T ATE323510T1 AT E323510 T1 ATE323510 T1 AT E323510T1 AT 98950742 T AT98950742 T AT 98950742T AT 98950742 T AT98950742 T AT 98950742T AT E323510 T1 ATE323510 T1 AT E323510T1
Authority
AT
Austria
Prior art keywords
apoa
agonists
apolipoprotein
treatment
native
Prior art date
Application number
AT98950742T
Other languages
English (en)
Inventor
Jean-Louis Dasseux
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Original Assignee
Jean-Louis Dasseux
Renate Sekul
Klaus Buttner
Isabelle Cornut
Gunther Metz
Jean Dufourcq
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean-Louis Dasseux, Renate Sekul, Klaus Buttner, Isabelle Cornut, Gunther Metz, Jean Dufourcq filed Critical Jean-Louis Dasseux
Application granted granted Critical
Publication of ATE323510T1 publication Critical patent/ATE323510T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98950742T 1997-09-29 1998-09-28 Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen ATE323510T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Publications (1)

Publication Number Publication Date
ATE323510T1 true ATE323510T1 (de) 2006-05-15

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950742T ATE323510T1 (de) 1997-09-29 1998-09-28 Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen

Country Status (17)

Country Link
US (4) US6518412B1 (de)
EP (1) EP1039934B1 (de)
JP (1) JP2003525565A (de)
KR (1) KR100650975B1 (de)
CN (1) CN100345588C (de)
AT (1) ATE323510T1 (de)
AU (1) AU758307B2 (de)
CA (1) CA2304814A1 (de)
DE (1) DE69834267T2 (de)
ES (1) ES2263221T3 (de)
HU (1) HU225821B1 (de)
IL (1) IL135324A0 (de)
NO (1) NO20001601L (de)
NZ (1) NZ503720A (de)
PL (1) PL193662B1 (de)
RU (1) RU2222545C2 (de)
WO (1) WO1999016409A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
CA2402772A1 (en) * 2000-03-13 2001-09-20 Amgen Inc. Apolipoprotein-a-i regulation of t-cell signalling
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7959659B2 (en) * 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
WO2006034056A2 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
ES2346771T3 (es) * 2004-10-15 2010-10-20 The Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Serv Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso.
EP1827472A4 (de) 2004-12-06 2012-09-05 Univ California Verfahren zur verbesserung der struktur und funktion von arteriolen
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
EP2041174A2 (de) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Neue, den lipidausstrom fördernde peptide
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
CA2660743C (en) * 2006-08-17 2015-11-24 The Uab Research Foundation Immunogenic pcpa polypeptides and uses thereof
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2682400B1 (de) * 2007-08-28 2017-09-20 Uab Research Foundation Synthetische Apolipoprotein E nachahmende Polypeptide und Anwendungsverfahren
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
RU2532222C2 (ru) * 2009-02-16 2014-10-27 Серенис Терапьютикс Холдинг С.А, Миметики аполипопротеина а-i
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
KR101631363B1 (ko) 2010-08-30 2016-06-17 에프. 호프만-라 로슈 아게 테트라넥틴 아포지방단백질 a-i, 이를 함유하는 지질 입자 및 이의 용도
CA2826158A1 (en) * 2011-02-07 2012-08-16 Rose ACKERMANN Lipoprotein complexes and manufacturing and uses thereof
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
CA2838070A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
EP3471778A4 (de) * 2016-06-20 2020-02-19 The Regents of The University of Michigan Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5733879A (en) 1992-06-12 1998-03-31 N.V. Innogenetics, S.A. Peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
EP0755268A1 (de) * 1994-04-11 1997-01-29 Baylor College Of Medicine Zusammensetzungen und verfahren zur behandlung von erkrankungen durch gentherapie
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
HU225821B1 (en) 2007-10-29
HUP0003924A2 (hu) 2001-01-29
EP1039934B1 (de) 2006-04-19
NO20001601D0 (no) 2000-03-28
ES2263221T3 (es) 2006-12-01
CN1303298A (zh) 2001-07-11
US6518412B1 (en) 2003-02-11
KR20010030806A (ko) 2001-04-16
RU2222545C2 (ru) 2004-01-27
CA2304814A1 (en) 1999-04-08
CN100345588C (zh) 2007-10-31
WO1999016409A2 (en) 1999-04-08
KR100650975B1 (ko) 2006-11-29
NO20001601L (no) 2000-05-26
EP1039934A4 (de) 2002-11-27
NZ503720A (en) 2002-10-25
EP1039934A1 (de) 2000-10-04
US6844327B2 (en) 2005-01-18
AU758307B2 (en) 2003-03-20
DE69834267T2 (de) 2007-01-04
US20080050351A1 (en) 2008-02-28
DE69834267D1 (de) 2006-05-24
US7250407B2 (en) 2007-07-31
US20050148513A1 (en) 2005-07-07
IL135324A0 (en) 2001-05-20
US20030208059A1 (en) 2003-11-06
AU9671498A (en) 1999-04-23
PL358529A1 (en) 2004-08-09
HUP0003924A3 (en) 2005-12-28
PL193662B1 (pl) 2007-03-30
JP2003525565A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
ATE323510T1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
ES2130177T3 (es) Tratamiento de poblaciones de celulas.
DE69839014D1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
MX9602993A (es) Hormona del crecimiento humano.
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
DE69831500T2 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
ATE332379T1 (de) Menschliche dnase resistent gegen actininhibitoren
WO1998011234A3 (en) Human protein kinases
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
FR2792651A1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
FR2773079B1 (fr) Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
DE60318882D1 (de) Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
BR9915537A (pt) Gene prv-1 e sua utilização
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties